<DOC>
	<DOCNO>NCT01507727</DOCNO>
	<brief_summary>This drug develop treat Hyponatremia . The primary purpose study verify efficacy safety seven-day repeated oral administration tolvaptan 15 , 30 , 60 mg placebo patient Non-hypovolemic Non-acute Hyponatremia secondary Congestive Heart Failure ( CHF ) , hepatic cirrhosis Syndrome Inappropriate Antidiuretic Hormone ( SIADH ) , despite receive standard therapy . This study conduct China .</brief_summary>
	<brief_title>Efficacy Safety Study Tolvaptan Tablets Patients With Non-hypovolemic Non-acute Hyponatremia</brief_title>
	<detailed_description />
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Inclusion Criteria ( CHF ) : 1 . Patients CHF exhibit edema , jugular venous distention , hepatomegaly , pulmonary congestion . 2 . Nonhypovolemic Nonacute hyponatremia serum sodium &lt; 135mEq/L randomization . 3 . Patients take furosemide 40 mg/d ( oral dosing ) without alteration dosage 3 day observation period . 4 . Patients whose body weight stable ( ±1.0 kg ) 2 day prior commencement study drug administration . 5 . Age:18～80 ( informed consent obtain ) ，male female . 6 . Inpatient subject . 7 . Informed consent . Inclusion Criteria ( hepatic cirrhosis ) : 1 . Patients hepatic edema . 2 . Nonhypovolemic non acute hyponatremia serum sodium &lt; 135mEq/L randomization . 3 . Age:18～65 ( informed consent obtain ) ，male female . 4 . Inpatient subject . 5 . Informed consent . Inclusion Criteria ( SIADH others ) : 1 . Patients SIADH arise variety etiology . 2 . Nonhypovolemic non acute hyponatremia serum sodium &lt; 135mEq/L randomization . 3 . Age:18～80 ( informed consent obtain ) ，male female . 4 . Inpatient subject . 5 . Informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>hyponatremia</keyword>
	<keyword>Non-hypovolemic Non-acute hyponatremia</keyword>
	<keyword>Tolvaptan</keyword>
</DOC>